The Human Cancer Models Initiative (HCMI) is an international collaboration between the NCI, Cancer Research UK, Wellcome Sanger Institute, and foundation Hubrecht Organoid Technology. The goal of HCMI is to create up to 1,000 patient-derived Next-generation Cancer Models such as organoids, conditionally reprogrammed cells, neurospheres, or optimal growth condition models as a community resource. HCMI aims to provide the models' case-associated data, which includes quality-checked clinical, biospecimen, and molecular characterization data from the models, the tissues from which they were derived, and normal tissues, when available. Available harmonized data are accessible through the NCI's Genomic Data Commons (GDC) or the European Bioinformatics Institute. The HCMI uses current culture techniques to develop cancer models for translational cancer research and other experiments.